Based on the provided context, there is no direct mention of “SMMT” or any related new product development. The context includes discussions about:
1. Integration efforts for SMB technology platforms like Cabbage Center
2. Biogen’s R&D pipeline and external innovation strategy (e.g., investment in Embryo Pharmaceuticals for Ninerifaxtat)
3. Infrastructure and operational standards for unmanned aerial vehicles (e.g., eVTOL ports, certification programs)
If “SMMT” refers to a specific term within this context, it is not explicitly defined or discussed. For accurate details, please clarify or provide additional context.